Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (3021)	4/9/2014 4:42:47 PM
From: scaram(o)uche	Respond to of 3202

#2 was first from this Zach guy, who is quite good, a week ago. So, my news is one week stale, give or take. :-) Blame Tuck. zach ?@zbiotech Apr 2 $GILD momelotinib combo w/chemo pII in front-line metastatic pancreatic cancer enrolling soon - http://clinicaltrials.gov/ct2/show/NCT02101021?term=Momelotinib&rank=1 … $INCY

To: scaram(o)uche who wrote (3021)	4/21/2014 11:44:07 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 3202

>> Gilead isn't letting cyt-387 moss grow under rux's rolling rock << And it _is_ rux's rolling rock, rather than 110's or 986's....... clinicaltrials.gov Interesting..... Janus 1 is nothing other than a scaled-up version of the phase II (which failed, minus subset evaluation). No biomarker!! Means that a "Janus 2" phase III (with inflammation biomarker) must be hot on heels of Janus 1?